Hologic Inc
HOLX: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $69.00 | Rdlgwh | Vdwpctybc |
Hologic Looks Forward to Stronger Molecular Diagnostic Business After Pandemic
/s3.amazonaws.com/arc-authors/morningstar/adf521c2-d9af-477d-a6bc-03ec7ca34c40.jpg)
Business Strategy and Outlook
Under CEO Stephen MacMillan's watch, Hologic has been able to focus on structural competitive advantages, improve its balance sheet, and judiciously step into complementary markets, which evens out the vagaries of product cycles. Hologic controls roughly 65% of the U.S. digital mammography market and leads the way in 3D mammography. While 3D adoption has slowed, Hologic's clinical data still gives it an edge over its larger competitors, and there are still opportunities to sell ancillary accessories for mammograms and biopsies.